<DOC>
	<DOCNO>NCT02060955</DOCNO>
	<brief_summary>The overall purpose study investigate efficacy safety ALECSAT patient relapse GlioBlastoma Multiforme ( GBM ) first line treatment ( follow reoperation possible ) . The efficacy safety ALECSAT treatment , compare standard Bevacizumab/Irinotecan second line treatment patient .</brief_summary>
	<brief_title>Randomized Phase 2 Study Investigate Efficacy ALECSAT Patients With GBM Measured Compared Avastin/Irinotecan</brief_title>
	<detailed_description>This study open-label , randomize , prospective , parallel group phase II study ALECSAT compare Bevacizumab/Irinotecan patient verify relapsed glioblastoma multiforme treatment recognise first-line treatment . After 62 PFS event record , interim analysis conduct auspex Data Monitoring Committee . The patient two treatment group follow 62 week plan study visit . Patients , least , stable disease continue allocate treatment study period judge Investigator . Patients allocated Bevacizumab/Irinotecan ( control group ) receive treatment accord standard praxis , i.e . 16 treatment cycle 4 week duration . Each cycle Bevacizumab/Irinotecan consist 2 dosing day ; day 1 day 15 cycle .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm GBM tumour recurrence complete recognize firstline treatment , tumor recurrence , document MRI , Minimum age 18 year old , Capable understanding information give informed consent Minimum height 155 cm Expected survival time ( life expectancy ) 3 month Adequate performance status equal 2 Clinically normal Erythrocyte Volume Fraction ( EVF ) Women fertile condition include negative pregnancy test screening must use appropriate contraceptive study Positive test HIV1/2 ; HBsAg , hemoglobin C , hepatitis C virus , positive Treponema Pallidum test ( syphilis ) Patients may expose West Nile virus , Dengue virus human Tcell lymphotrophic virus ( HTLV1 ) virus exclude , unless patient test negative Concurrent illness , e.g . uncontrolled epilepsy , cardiovascular , cerebrovascular , and/or respiratory disease worsen cause complication connection blood donation Clinically significant autoimmune disorder condition immune suppression Hemoglobin count ≤ 7.5mmol/l ( men &amp; woman ) Lymphocytenumbers 0.5 x 109/l Body weight 40 kg ( men ) 50 kg ( woman ) Clinically abnormal ECG judge Investigator Pregnant breast feeding woman Inclusion clinical study 4 week prior inclusion study Any medical condition render participation study risky , accord Investigator make assessment study endpoint difficult Treatment immunotherapy , cytotoxic therapy , biologic therapy 4 week prior enrolment study Patients either may put risk due blood donation expect ALECSAT product good quality produce , judge Investigator Patients uncontrolled serious bacterial , viral , fungal parasitic infection Blood transfusion within 48 hour prior donation blood ALECSAT production Known suspect intolerance Avastin , Irinotecan excipients well intolerance recombinant humanize antibody Performance status ≥ 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Bevacizumab/Irinotecan</keyword>
	<keyword>ALECSAT</keyword>
	<keyword>recurrent</keyword>
</DOC>